Uveitis is the inflammation of uvea which consists of the iris, ciliary body, and choroid. Uveitis affects approximately 3 million patients in China with ~60% classified as NIAU. Uveitis may recur ...

VivaVision Biotech (VivaVision), a clinical-stage, privately held biotechnology company focused on developing innovative treatments for ocular diseases, today announced positive topline results from ...

VVN461, a dual JAK1/TYK2 inhibitor as a non-steroidal anti-inflammatory agent, has met primary endpoints, demonstrating non-inferior efficacy compared to the standard therapy, prednisolone acetate ...

Heterochromia is a phenomenon that occurs when a person's irises are different colors. This condition is not particularly common. In fact, heterochromia can be partial, meaning tha ...

VVN461, a dual JAK1/TYK2 inhibitor as a non-steroidal anti-inflammatory agent, has met primary endpoints, demonstrating non-inferior efficacy compared to the standard therapy, prednisolone acetate (PA ...

Attendance Allowance could help people who are severely short-sighted or have eye conditions including cataract, glaucoma or macular degeneration.

VivaVision plans discussions with Chinese CDE and FDA for phase 3 trials, aiming to provide a non-steroidal treatment option for uveitis. VivaVision Biotech has announced the positive topline results ...

Int Ophthalmol Clin. 2015;55(3):111-131.

Join MIMS now and pay nothing for the first 30 days Join GPOnline now and pay nothing for the first 30 days ...